Recent investigations have converged on the overlap of GLP-1|GIP|GCGR stimulant therapies and DA signaling. While GLP agonists are commonly employed for treating type 2 diabetes mellitus, their unexpected impacts on https://tiannaohoc569685.techionblog.com/41252935/emerging-glp-activators-and-dopaminergic-influence-a-comparative-assessment